Nanomics Biotechnology Co., Ltd. controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2026
US ITC issues partial final determination in Section 337 investigation with Nanomics Biotechnology as default respondent
Ruling
On October 13, 2026, the U.S. International Trade Commission (ITC) announced a partial final determination in its Section 337 investigation (No. 337-TA-1508) concerning certain systems, devices, software, compositions, chemicals, and laboratory supplies for studying proteins. The Commission declined to review the administrative law judge's September 16, 2026 initial determination (No. 7), under which the sole named respondent, Nanomics Biotechnology Co., Ltd. (珞米生命科技) of Hangzhou, Zhejiang, China, was found in default, and recommended remedies of a general exclusion order and cease-and-desist order. Interested parties, government agencies, and individuals may submit comments on the recommended remedies, public interest, and bond of no more than 15 pages by October 30, 2026.
Source excerpt
对本案行政法官于2026年9月16日作出的初裁（No.7）不予复审，即唯一的列名被告中国浙江Nanomics Biotechnology Co., Ltd., of Hangzhou, China珞米生命科技为缺席被告，建议救济措施为普遍排除令和禁止令
2026年10月13日，美国国际贸易委员会（ITC）发布公告称，对特定用于研究蛋白质的系统、设备、软件、组合物、化学品和实验室用品（Certain Systems, Devices, Software, Compositions, Chemicals, and Laboratory Supplies for Studying Proteins，调查编码：337-TA-1508）作出337部分终裁
案件双方、利益相关政府机构和个人等都可就建议救济措施、公众利益和保证金等提交意见，主要考虑公众健康和福利、美国经济中的竞争状况、与正在调查的产品相似或直接竞争的美国生产的产品、美国消费者，书面材料不多于15页、不晚于2026年10月30日提交。